Erik L. Kimble

757 total citations
31 papers, 218 citations indexed

About

Erik L. Kimble is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Erik L. Kimble has authored 31 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 9 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Erik L. Kimble's work include CAR-T cell therapy research (20 papers), Biosimilars and Bioanalytical Methods (5 papers) and Cytomegalovirus and herpesvirus research (5 papers). Erik L. Kimble is often cited by papers focused on CAR-T cell therapy research (20 papers), Biosimilars and Bioanalytical Methods (5 papers) and Cytomegalovirus and herpesvirus research (5 papers). Erik L. Kimble collaborates with scholars based in United States, Australia and Switzerland. Erik L. Kimble's co-authors include Krishna V. Komanduri, José F. Camargo, Cara L. Benjamin, Eric Wieder, Juan Pablo Alderuccio, Jeremy Ramdial, Isildinha M. Reis, Nicolas Gallastegui, Jennifer R. Chapman and Amrita Desai and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Erik L. Kimble

26 papers receiving 217 citations

Peers

Erik L. Kimble

ONCOL

EPIDE

PFM

IMMUN

GENET

J Maertens Belgium

Maite Encuentra Spain

J. Gottlieb France

Varun Mehra United Kingdom

Helena Pomares Spain

Laure Lebras France

Miki Shirakawa Garcia United States

Hidekazu Itamura Japan

Sérgio Roithmann Brazil

Wolf Rösler Germany

J Maertens Belgium

Erik L. Kimble

112 ×1.1

ONCOL

56 ×0.6

EPIDE

102 ×1.2

PFM

30 ×0.8

IMMUN

43 ×1.2

GENET

Citations per year, relative to Erik L. Kimble Erik L. Kimble (= 1×) peers J Maertens

Countries citing papers authored by Erik L. Kimble

Since Specialization

Citations

This map shows the geographic impact of Erik L. Kimble's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik L. Kimble with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik L. Kimble more than expected).

Fields of papers citing papers by Erik L. Kimble

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik L. Kimble. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik L. Kimble. The network helps show where Erik L. Kimble may publish in the future.

Co-authorship network of co-authors of Erik L. Kimble

This figure shows the co-authorship network connecting the top 25 collaborators of Erik L. Kimble. A scholar is included among the top collaborators of Erik L. Kimble based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik L. Kimble. Erik L. Kimble is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gauthier, Jordan, Emily C. Liang, Jennifer J. Huang, et al.. (2025). Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL. Blood Advances. 9(8). 1861–1872.

Cao, Yue, Ye Zheng, Janaki Purushe, et al.. (2024). Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming. Blood. 144(Supplement 1). 2028–2028. 1 indexed citations

Huang, Jennifer J., Emily C. Liang, Andrew J. Portuguese, et al.. (2024). Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.. Journal of Clinical Oncology. 42(16_suppl). 7034–7034. 2 indexed citations

Laszlo, George S., Erik L. Kimble, Tinh-Doan Phi, et al.. (2024). Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy. SHILAP Revista de lepidopterología. 32(3). 200854–200854. 5 indexed citations

Zheng, Ye, Janaki Purushe, Jay F. Sarthy, et al.. (2024). Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion. Nature Communications. 15(1). 8309–8309. 4 indexed citations

Portuguese, Andrew J., Jennifer J. Huang, Emily C. Liang, et al.. (2024). Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity. Transplantation and Cellular Therapy. 30(2). S192–S192. 7 indexed citations

Fiorenza, Salvatore, Erik L. Kimble, Alexandre V. Hirayama, et al.. (2023). Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study. Transplantation and Cellular Therapy. 29(2). S13–S13. 1 indexed citations

Voutsinas, Jenna, Andrew J. Portuguese, Jennifer J. Huang, et al.. (2023). Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel. Blood. 142(Supplement 1). 2126–2126. 1 indexed citations

Liang, Emily C., Alexandre V. Hirayama, Erik L. Kimble, et al.. (2023). Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.. Journal of Clinical Oncology. 41(16_suppl). 7511–7511.

10.

Liang, Emily C., Jennifer J. Huang, Alexandre V. Hirayama, et al.. (2023). Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Advances. 7(22). 6990–7005. 14 indexed citations

11.

Portuguese, Andrew J., Emily C. Liang, Jennifer J. Huang, et al.. (2023). Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting. Blood. 142(Supplement 1). 2131–2131. 2 indexed citations

12.

Kimble, Erik L., Alexandre V. Hirayama, Barbara S. Pender, et al.. (2022). CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study. Blood. 140(Supplement 1). 10363–10365. 2 indexed citations

13.

Boeckh, Michael, et al.. (2021). 924. Cytomegalovirus (CMV) Retinitis during Maintenance Chemotherapy for Acute Lymphoblastic Leukemia. Open Forum Infectious Diseases. 8(Supplement_1). S553–S554.

14.

Camargo, José F., Anthony D. Anderson, Rossana Rosa, et al.. (2019). Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients. Transplant Infectious Disease. 21(2). 4 indexed citations

15.

Alderuccio, Juan Pablo, Wei Zhao, Amrita Desai, et al.. (2019). Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. American Journal of Hematology. 94(5). 585–596. 26 indexed citations

16.

Alderuccio, Juan Pablo, Wei Zhao, Amrita Desai, et al.. (2018). Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. Journal of Clinical Oncology. 36(34). 3370–3380. 47 indexed citations

17.

Camargo, José F., Eric Wieder, Erik L. Kimble, et al.. (2018). Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. Blood. 133(8). 867–877. 36 indexed citations

18.

Camargo, José F., Erik L. Kimble, Rossana Rosa, et al.. (2017). Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation. 24(4). 806–814. 49 indexed citations

19.

Desai, Amrita, Amer Beitinjaneh, Jeremy Ramdial, et al.. (2017). Safety of High-Dose Melphalan (200 Mg/M2) as Conditioning for Autologous Stem Cell Transplantation for Myeloma in Elderly Patients. Biology of Blood and Marrow Transplantation. 23(3). S133–S134. 2 indexed citations

20.

Kimble, Erik L., et al.. (2017). Telemedicine: A Modern Application in the Treatment of Chronic Hepatitis C Infection. Gastroenterology. 152(5). S847–S848. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact